### Bioresearch Monitoring (BIMO) Metrics – FY'13


### **BIMO Inspections Completed FY 2013**

Center	CI	<u>IRB</u>	Spon/CRO	GLP	<u>Total</u>
CBER	91	8	4	1	104
CDER*	344	90	62	28	524
CDRH	193	76	53	10	332
CFSAN**	0	0	0	0	0
CVM	36	na	1	22	59
All Centers	664	174	120	61	1019

<sup>\*3</sup> IRB = RDRC; + 205 BEQ inspections (CDER specific) ⇒ total = 1224

<sup>\*\*</sup>CFSAN's BIMO Program remains under reorganization

# FY'13 CI Inspections Classified\* All Centers




<sup>\*</sup>inspections classified in FY'13 no matter when inspection occurred

### **Most Common CI Deficiencies**

- Failure to follow the investigational plan and/or regulations
- Protocol deviations
- Inadequate recordkeeping
- Inadequate accountability for the investigational product
- Inadequate communication with the IRB
- Inadequate subject protection failure to report AEs and informed consent issues

### FY'13 IRB Inspections Classified\* – All Centers




<sup>\*</sup>inspections classified in FY'13 no matter when inspection occurred

#### Most common IRB deficiencies

- Inadequate initial and/or continuing review
- Inadequate SOPs
- Inadequate membership rosters
- Inadequate meeting minutes
- Quorum issues
- Subpart D issues
- Inadequate communication with CI/institution

Specific to devices – lack of or incorrect SR/NSR determination

FY'13 Sponsor/Monitor/CRO Inspections Classified\* – All Centers




<sup>\*</sup>inspections classified in FY'13 no matter when inspection occurred

#### Most common S/M deficiencies

- Inadequate monitoring
- Failure to bring investigators into compliance
- Inadequate accountability for the investigational product
- Failure to obtain FDA and/or IRB approval prior to study initiation

### FY'13 BEQ inspections classified\*




<sup>\*</sup>inspections classified in FY'13 no matter when inspection occurred

#### Most common BEQ deficiencies

- Recordkeeping
- Inclusion/exclusion criteria issues
- Informed consent issues
- Dosage issues
- Analytical concerns
  - Validation
  - Stability
- Inadequate SOPs

## FY'13 GLP inspections classified\* All Centers



<sup>\*</sup>inspections classified in FY'13 no matter when inspection occurred


#### Most common GLP deficiencies

- Organizational and/or Personnel inadequacies
- Incomplete/inadequate/no study records
- Inadequate archiving
- Inadequate/no standard operating procedures (SOPs)
- Protocol deviations

# International Inspections Completed: FY 2013


Center	<u>CI</u>	Sponsor	GLP	BEQ	<u>Total</u>
CBER	24				24
CDER	98		2	102	202
CDRH	12	6	2		20
Totals	134	6	4	102	246

# FY'13 International CI Inspections Classified\* – All Centers



<sup>\*</sup>inspections classified in FY'13 no matter when inspection occurred

# **FY'13 International BEQ Inspections Classified\***



<sup>\*</sup>inspections classified in FY'13 no matter when inspection occurred

# Other International Inspections Classified in FY'13\*

#### Sponsor/CRO

CDER – 5 NAI, 1 VAI; CDRH – 1 VAI, 1 OAI

#### **GLP**

CDER – 1 VAI; CDRH – 1 NAI

<sup>\*</sup>inspections classified in FY'13 no matter when inspection occurred

## Common international deficiencies

- Similar to domestic inspectional findings
- Sponsor inspections
  - Inadequate monitoring
  - Failure to bring investigators into compliance
- Cl inspections
  - Protocol deviations
  - Inadequate investigational product accountability
  - Inadequate subject protections